Refine
Document Type
- Article (2)
- Part of a Book (1)
Language
- English (3)
Has Fulltext
- yes (3)
Is part of the Bibliography
- no (3)
Keywords
- 177Lu-PSMA-617 (2)
- PSMA (2)
- 223Radium-dichloride (1)
- Anlaut (1)
- Auslaut (1)
- Hematologic adverse events (1)
- Hematotoxicity (1)
- Metastatic castration-resistant prostate cancer (1)
- Phonologie (1)
- Silbe (1)
Institute
- Medizin (2)
Bone-seeking 223Radium-dichloride (223Ra) is an established treatment prolonging survival and reducing morbidity in selected patients with metastatic castration-resistant prostate cancer (mCRPC) with skeletal involvement. Radioligand therapy with 177Lutetium-PSMA-617 (177Lu-PSMA-617) has been increasingly implemented in patients with mCRPC failing conventional treatment options. In this study, the safety and efficacy of 177Lu-PSMA-617 in patients with progressive bone involvement under treatment with 223Ra was assessed. Twenty-eight men (median age 73 years, range 63–89 years) with progressive mCRPC, who started 177Lu-PSMA-617 within 8 weeks after the last 223Ra administration, received a median of 4 (IQR 3–6) and a total of 120 cycles of 223Ra and a median of 4 (IQR 2–7) cycles 177Lu-PSMA-617 with a mean treatment activity of 6.5 ± 1.2 GBq per cycle, reaching a mean cumulative activity of 30.7 ± 23.4 GBq. A PSA response (≥50% PSA decline 12 weeks after the first 177Lu-PSMA-617 cycle) was observed in 18/28 (64.3%) patients and imaging-based partial remission (PR) was observed in 11/28 (39.3%) patients. Median imaging-based progression-free survival (PFS) was 10 (95% CI, 6–14) months and median overall survival (OS) was 18 (95% CI, 14–22) months. Patients with low bone tumor burden (2–20 lesions) had a significantly longer OS (28 vs. 14 months, p < 0.045) compared to patients with a high tumor burden (>20 lesions). Grade ≥ 3 hematological toxicity was observed in six patients after their last treatment cycle with anemia, leukopenia and thrombocytopenia in 5/28 (17.9%), 4/28 (14.3%) and 6/28 (21.4%) patients, respectively. In progressive bone-metastatic mCRPC patients, prompt initiation of 177Lu-PSMA-617 after failing 223Ra is effective with an acceptable toxicity profile.
Background: Myelosuppression is a potential dose-limiting factor in radioligand therapy (RLT). This study aims to investigate occurrence, severity and reversibility of hematotoxic adverse events in patients undergoing RLT with 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC). The contribution of pretreatment risk factors and cumulative treatment activity is taken into account specifically. Methods: RLT was performed in 140 patients receiving a total of 497 cycles. A mean activity of 6.9 ± 1.3 GBq 177Lu-PSMA-617 per cycle was administered, and mean cumulative activity was 24.6 ± 15.9 GBq. Hematological parameters were measured at baseline, prior to each treatment course, 2 to 4 weeks thereafter and throughout follow-up. Toxicity was graded based on Common Terminology Criteria for Adverse Events v5.0. Results: Significant (grade ≥ 3) hematologic adverse events occurred in 13 (9.3%) patients, with anemia in 10 (7.1%), leukopenia in 5 (3.6%) and thrombocytopenia in 6 (4.3%). Hematotoxicity was reversible to grade ≤ 2 through a median follow-up of 8 (IQR 9) months in all but two patients who died from disease progression within less than 3 months after RLT. Myelosuppression was significantly more frequent in patients with pre-existing grade 2 cytopenia (OR: 3.50, 95%CI 1.08–11.32, p = 0.04) or high bone tumor burden (disseminated or diffuse based on PROMISE miTNM, OR: 5.08, 95%CI 1.08–23.86, p = 0.04). Previous taxane-based chemotherapy was associated with an increased incidence of significant hematotoxicity (OR: 4.62, 95%CI 1.23–17.28, p = 0.02), while treatment with 223Ra-dichloride, cumulative RLT treatment activity and activity per cycle were not significantly correlated (p = 0.93, 0.33, 0.29). Conclusion: Hematologic adverse events after RLT have an acceptable overall incidence and are frequently reversible. High bone tumor burden, previous taxane-based chemotherapy and pretreatment grade 2 cytopenia may be considered as risk factors for developing clinically relevant myelosuppression, whereas cumulative RLT activity and previous 223Ra-dichloride treatment show no significant contribution to incidence rates.
In this paper we focus on the similarities tying together the second segment of an onset cluster and a singleton coda segment. We offer a proposal based on Baertsch (2002) accounting for this similarity and show how it captures a number of observations which have defied previous explanation. In accounting for the similarity of patterning between the second member of an onset and a coda consonant, we propose to augment Prince & Smolensky's (P&S, 1993/2002) Margin Hierarchy so as to distinguish between structural positions that prefer low sonority and those that prefer high sonority. P&S's Margin Hierarchy, which gives preference to segments of low sonority, applies to singleton onsets; this is our M1 hierarchy. Our proposed M2 hierarchy applies both to the second member of an onset and to a singleton coda. The M2 hierarchy differs from the M1 hierarchy in giving preference to consonants of high sonority. Splitting the Margin Hierarchy into the M1 and M2 hierarchies allows us to explain typological, phonotactic, and acquisitional observations that have defied previous explanation. In Section 2 of this paper, we briefly provide background on the links that tie together the second member of an onset and a singleton coda. In Section 3, we review P&S's Margin Hierarchy, showing that it becomes problematic when extended to coda consonants. We then offer our proposal for a split margin hierarchy. Section 4 extends the split margin approach to complex onsets. We then show how it is able to account for various typological, phonotactic, and acquisitional observations. In Section 5, we will conclude the paper by briefly sketching how the split margin approach enables us to analyze syllable contact phenomena without requiring a specific syllable contact constraint (or additional hierarchy) or reference to an external sonority scale.
